Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2018

View Archived Issues

Series A financing to support Modis' development of MT-1621 for thymidine kinase 2 deficiency

Gallium has antibiotic properties and improves lung function in humans with chronic lung infections

Researchers link FCN3 to mortality in patients with type 1 diabetes

Mutations in RIPPLY3 gene cause conotruncal heart defects in Han Chinese

Knockout of HRD1 protects mice from high fat diet-induced obesity

CXCL14 downregulation as novel therapeutic strategy in type 2 diabetes

CD44 as novel therapeutic target in diabetes

Researchers identify Lrrc55 as potential new target in pancreatic beta cells

A Finnish founder mutation in junctophilin-2 causes hypertrophic cardiomyopathy

Humira goes to Stockholm: Three win Chemistry Nobels for protein engineering methods

Go Therapeutics and Roche enter license agreement to develop glycotargeting bispecific antibody

OncoTherapy Science patents SUV39H2 inhibitors

Encouraging initial data presented from two ongoing studies of Trappsol Cyclo in NPC

Pfizer identifies LRRK2 inhibitors

Yogee's Bioinnovations discloses cathepsin D and angiogenesis inhibitors

French researchers patent new beta-lactamase inhibitors

Theravance Biopharma divulges JAK inhibitors

Jiangsu Alphamab initiates first-in-human trial of KN-026 for advanced breast and gastric cancer

Boston expands pipeline through licensing deals with Novartis and GSK

Que Oncology opens phase II trial of Q-122 to treat vasomotor symptoms in breast cancer patients

Eagle enters agreement with USAMRICD to evaluate neuroprotective effects of Ryanodex

Medivir reports phase I data from ongoing study of birinapant with Keytruda in advanced solid tumors

VE-303 results in accelerated gut microbiota restoration after antibiotics in phase I study

Eisai studies E-2730 in adults with photosensitive epilepsy

Tumor-specific peptide-conjugated siRNA targeting CDCA1 effectively treats prostate cancer in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...